吴喜林博士
研究员/助理教授/博导
电话:邮箱:xilinwu@nju.edu.cn 地址:必赢76net线路 鼓楼校区 必赢76net线路科研中心楼研究方向:
1.纳米抗体药物研究 2.人工智能纳米抗体药物研发 3.病毒感染的防治及致病机制研究 香港大学博士 研究员/助理教授/博导 中国生物工程学会抗体委员会委员 主要研究方向:1)病毒感染的防治及致病机制研究,2)纳米抗体药物研究,3)人工智能纳米抗体药物研发,4)基于纳米抗体的工程改造,基因治疗和细胞治疗。致力于针对传染病的新型生物医药研发与机制探讨,并构建了具有自主产权的纳米抗体药物研发平台和多靶向抗体改造和AAV递送抗体平台。 获得的荣誉称号:江苏省双创博士、江苏省六大人才高峰 B类人才, 南京市高层次人才、第十五届江苏省青年五四奖章集体。 发表SCI论文20余篇,以近5年来第一作者或通讯作者在Nature Communications、J Clin Invest、Cell Reports、EMBO Molecular Medicine、JCI Insight、Plos pathogen (x2)等国际高水平学术期刊发表论文10余篇,平均IF大于10分;获批14项国内、日本或美国的发明专利,其中3项已实现成果转化。作为项目负责人主持国家级(2项)、省(3项)、市等各类基金11项,获批科研经费累计超过300万;作为任务级负责人参与国家十三五传染病重大专项课题一项。 中国生物工程学会抗体委员会委员 1. Zhu L, Huang B, Wang X, Ni F, Ao M, Wang R, Zheng B, Chen C, Xue J, Zhu L, Yang C, Shi L, Geng S, Hu J, Yang M, Zhang D, Yang P, Li M, Li Y, Hu Q, Ye S, Zheng P, Wei H, Wu Z(*), Zhang L(*), Wang Y(*), Liu Y(*), Wu X(*). Highly potent and broadly neutralizing anti-CD4 trimeric nanobodies inhibit HIV-1 infection by inducing CD4 conformational alteration.Nature Communications. 2024;15(1):6961. (通讯作者) 2. Ji, M., J. Hu, D. Zhang, B. Huang, S. Xu, N. Jiang, Y. Chen, Y. (*)Wang, X. Wu (*) and Z. Wu(*) (2024). Inhibition of SFTSV replication in humanized mice by a subcutaneously administered anti-PD1 nanobody. EMBO molecular medicine16(3): 575-595. (共同通讯) 3. Wu, Xilin,Lin Cheng, Ming Fu,….Yalan Liu (*) and Zhiwei Wu(*) (2021) . A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.. Cell Reports. 2021: p. 109869-109869.(第一作者) (研发了一种通过吸入式给药治疗新冠病毒感染的新型纳米抗体,该项目在2020年五四青年节获得江苏省委领导的参观和表彰,并获得2020年江苏省青年五四奖章集,排名第一)。 4. Nawaz, W., B. Huang, S. Xu, Y. Li, L. Zhu, H. Yiqiao, Z. Wu(*) and Xilin Wu (*) (2021). AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia. Blood cancer journal11(6): 119-119. (通讯作者) 5. Huang, B., L. Zhu, H. Wei, H. Shi, D. Zhang, H. Yuan, L. Luan, N. Zheng, S. Xu, W. Nawaz, Y. Hong, X. Wu(*)and Z. Wu(*) (2021). Potent Neutralizing Humanized Antibody With Topical Therapeutic Potential Against HPV18-Related Cervical Cancer.Frontiers in Immunology12(2339).(共同通讯) 6. Xu, S., N. Jiang, W. Nawaz, B. Liu, F. Zhang, Y. Liu, X. Wu (*)and Z. Wu(*)(2021). Infection of humanized mice with a novel phlebovirus presented pathogenic features of severe fever with thrombocytopenia syndrome. PLoS pathogens17(5): e1009587-e1009587. (共同通讯) 7. Xilin Wu (#), Yanlei Li(#),Bilian Huang, , Xiaohua Ma, Linjing Zhu, Nan Zheng, Shijie Xu, Waqas Nawaz, Changping Xu, Zhiwei Wu (*)A single domain antibody inhibits SFTSV infection and mitigates virus-induced pathogenesis in vivo, JCI Insight, 2020,5(13).(第一作者)(项目成果入选国家“十三五”科技创新成果展) 8. Xiaoyan Tian; Deyan Chen; Huanru Wang; Shijie Xu; Linjing Zhu; Xilin Wu (*); Zhiwei Wu (*); The Induction and Characterization of Monoclonal Antibodies Specific to GP of Ebola Virus, Journal of Medical Virology, 2019, 2020: 1-11. (共同通讯) 9. Nawaz, W., Xu, S., Li, Y., Huang, B., Wu, X.(*), & Wu, Z. (*). Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy. Acta biomaterialia 109, 21-36, doi:10.1016/j.actbio.2020.04.015 (2020).(共同通讯) 10. Xilin Wu; Xiaohua Ma; Yanlei Li; Yue Xu; Nan Zheng; Shijie Xu; Waqas Nawaz; Zhiwei Wu, Induction of neutralizing antibodies by human papillomavirus vaccine generated in mammalian cells, Antibody Therapeutics, 2019.3, 2(2) (封面) (第一作者) 11. Wu, Xilin; Guo, Jia; Niu, Mengyue; An, Minghui; Liu, Li; Wang, Hui; Jin, Xia; Zhang, Qi; Lam, Ka Shing; Wu, Tongjin; Wang, Hua; Wang, Qian; Du, Yanhua; Li, Jingjing; Cheng, Lin; Tang, Hang Ying; Shang, Hong; Zhang, Linqi; Zhou, Paul; Chen, Zhiwei(*), Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice. Journal of Clinical Investigation, 2018. 128(6):2239-2251 (第一作者)(首次研发的AAV递呈的双靶向抗体药物首次在小鼠动物模型治愈了HIV感染,被国家卫健委科技教育司评为2018年最具影响力的十大科研成果之一) 12. Wu, Xilin; Liu, Li; Cheung, Ka-Wai; Wang, Hui; Lu, Xiaofan; Cheung, Allen Ka Loon; Liu, Wan; Huang, Xiuyan; Li, Yanlei; Chen, Zhiwei W; Chen, Samantha M Y; Zhang, Tong; Wu, Hao; Chen, Zhiwei(*), Brain Invasion by CD4(+) T Cells Infected with a Transmitted/Founder HIV-1BJZS7 During Acute Stage in Humanized Mice., J Neuroimmune Pharmacol, 2016.9, 11(3):572 ~ 583(第一作者) 13. Song, P., N. Zheng, Y. Liu, C. Tian, X. Wu, X. Ma, D. Chen, X. Zou, G. Wang, H. Wang, Y. Zhang, S. Lu, C. Wu and Z. Wu (2018). Deficient humoral responses and disrupted B-cell immunity are associated with fatal SFTSV infection. Nat Commun 9(1): 3328. 14. Cheung, Allen Ka Loon; Kwok, Hau-Yee; Huang, Yiru; Chen, Min; Mo, Yufei; Wu, Xilin; Lam, Ka-Shing; Kong, Hoi-Kuan; Lau, Terrence Chi Kong; Zhou, Jingying; Li, Jingjing; Cheng, Lin; Kiat Lee, Boon; Peng, Qiaoli; Lu, Xiaofan; An, Minghui; Wang, Hui; Shang, Hong; Zhou, Boping; Wu, Hao; Xu, Aimin; Yuen, Kwok-Yung; Chen, Zhiwei(*), Gut-homing Delta42PD1(+)Vdelta2 T cells promote innate mucosal damage via TLR4 during acute HIV type 1 infection.,Nature Microbiology, 2017.10, 2(10):1389 ~ 1402 15. Yu, Zhe; Tan, Zhiwu(#); Lee, Boon Kiat; Tang, Jiansong; Wu, Xilin; Cheung, Ka-Wai; Lo, Nathan Tin Lok; Man, Kwan; Liu, Li; Chen, Zhiwei(*), Antigen spreading-induced CD8(+)T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells, Oncotarget, 2015.10.20, 6(32):32426 ~ 32438 16. Cheng, Lin; Tang, Xian; Liu, Li; Peng, Jie; Nishiura, Kenji; Cheung, Allen Ka Loon; Guo, Jia; Wu, Xilin; Tang, Hang Ying; An, Minghui; Zhou, Jingying; Cheung, Ka Wai; Wang, Hui; Guan, Xinyuan; Wu, Zhiwei(*); Chen, Zhiwei(*), Monoclonal antibodies specific to human Delta 42PD1: A novel immunoregulator potentially involved in HIV-1 and tumor pathogenesis, mAbs, 2015.5.4, 7(3):620 ~ 629 17. Guo, Jia; Zuo, Teng; Cheng, Lin; Wu, Xilin; Tang, Jiansong; Sun, Caijun; Feng, Liqiang; Chen, Ling; Zhang, Linqi; Chen, Zhiwei(*), Simian Immunodeficiency Virus Infection Evades Vaccine-Elicited Antibody Responses to V2 Region, JAIDS: Journal of Acquired Immune Deficiency Syndromes, 2015.4.15, 68(5):502 ~ 510 18. Chu, Ying; Li, Jiahuang; Wu, Xilin; Hua, Zichun; Wu, Zhiwei(*), Identification of human immunodeficiency virus type 1 (HIV-1) gp120-binding sites on scavenger receptor cysteine rich 1 (SRCR1) domain of gp340, Journal of Biomedical Science, 2013.7.1, 20 19. Yuan, Zhongping; Wu, Xilin; Liu, Chao; Xu, Genxing; Wu, Zhiwei(*), Asymmetric siRNA: New Strategy to Improve Specificity and Reduce Off-Target Gene Expression, Human Gene Therapy, 2012.5, 23(5):521 ~ 532 Ø 出版的论著 1. Wu X, Zhang J, Fang L. Next-Generation Sequencing and Proteomics-Enabled Approach for Rapid and High-Throughput Isolation of Virus-Neutralizing Nanobodies. Methods Mol Biol. 2024;2824:135-46.主持: 国家自然科学基金面上项目 国家自然科学基金青年项目 江苏省自然科学青年基金项目 江苏省双创博士 江苏省六大人才高峰 B类人才 南京市高层次人才 参与: 国家十三五传染病重大专项(任务级负责人) 第十五届江苏省青年五四奖章集体(排名第一) |